Chinese Tech Stocks Making Gains this Month

Chinese stocks, like their U.S. counterparts, hit the ground running in the first four months of 2019 amid hopes of a mutually beneficial trade deal between the United States and China. Things unraveled in May when trade tensions erupted between the two economic superpowers that resulted in both countries imposing a raft of new tariffs on each other.

China's finance ministry said Monday that it planned to ease restrictions on how the proceeds from special-purpose local government bonds were spent and encourage banks to offer loans to projects funded by such debt. The People's Bank of China hopes that the economic stimulus will offset U.S. President Donald Trump's threat of additional tariffs by boosting infrastructure investment. China's Shanghai Composite Index (000001.SS) climbed 2.6% – its biggest one-day gain since May 10 – after the ministry announced the latest measure to kickstart the world's second largest economy.

Traders who want exposure to China's economy should monitor these three large-cap Chinese companies listed on U.S. exchanges. Although these stocks remain highly sensitive to ongoing trade negotiations, they also stand to benefit from China's extensive stimulus initiatives. Let's take a closer look at each issue and its chart.

Read the full article at Investopedia.

Don’t Stop Here

More To Explore

ZTS: 3 Key Takeaways for Savvy Investors!

Disclaimer: This report is for informational and educational purposes only and does not constitute professional financial or investment advice. Furthermore, mentions of specific veterinary therapeutics

PAHC Q1 Earnings: Key Metrics You Can’t Ignore!

The synthesis of this valuation gap requires understanding market dynamics. Investors assign premium multiples to companion animal health businesses (like Idexx Laboratories or the companion

FLYW Q3 Call Reveals Game-Changing Insights!

Adyen (ADYEN.AS): A dominant European horizontal player trading at significantly higher growth multiples—commanding a ~5.0x EV/Revenue multiple and ~21.6x forward EV/EBITDA [cite: 1, 2]—largely due